Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Noelle Crompton"'
Autor:
Reinhard Marks, Giulia Quaresmini, Madlaina Breuleux, Noelle Crompton, Michelle Boyer, Richard Greil, Gianpietro Semenzato, Graeme Fraser, William Schary, Kathryn Humphrey, Brian Leber, Paula Marlton, J. Moritz Middeke
Publikováno v:
HemaSphere. 3:527
Autor:
Richard Greil, Gianpietro Semenzato, Giulia Quaresmini, Noelle Crompton, Michelle Boyer, Graeme Fraser, William Schary, Jan Moritz Middeke, Madlaina Breuleux, Kathryn Humphrey, Brian Leber, Paula Marlton, Reinhard Marks
Publikováno v:
Blood. 132:5548-5548
Introduction: The management of CLL has been transformed in recent years by the introduction of a number of targeted agents including the BCL2 inhibitor VEN, and the Bruton's tyrosine kinase inhibitor IBR. In the US and EU, VEN is currently approved
Autor:
Kathryn Humphrey, Alexandra Bazeos, Francine Swann, Nelson Kinnersley, Othman Al-Sawaf, Noelle Crompton, Craig Gower, Günter Fingerle-Rowson, Peter Trask, Mark Dixon, Valentin Goede
Publikováno v:
Blood. 128:4352-4352
BACKGROUND The evaluation of response to therapy in CLL is widely assessed according to the iwCLL guidelines which define progressive disease (PD) as advancing lymphocytosis, lymphadenopathy, organomegaly, cytopenias or histological transformation (H
Autor:
Marianne Uguen, Heinz Ludwig, Joerg Maurer, Günter Fingerle-Rowson, Kirsten Fischer, George A Follows, Michael Hallek, Francesc Bosch, Valentin Goede, Henrik Frederiksen, Noelle Crompton, Antonio Cuneo
Publikováno v:
Goede, V, Fischer, K, Bosch, F, Follows, G, Frederiksen, H, Cuneo, A, Ludwig, H, Crompton, N, Maurer, J, Uguen, M, Fingerle-Rowson, G & Hallek, M 2015, ' Updated survival analysis from the CLL11 study: Obinutuzumab versus rituximab in chemoimmunotherapy-treated patients with chronic lymphocytic leukemia ', 57th American Society of Hematology Annual Meeting and Exposition, Orlando, United States, 04/12/2015-08/12/2015 . < https://ash.confex.com/ash/2015/webprogram/Paper80155.html >
University of Southern Denmark
University of Southern Denmark
Introduction: Optimized therapeutic targeting of CD20 is one among several currently explored strategies to improve the overall prognosis of patients with chronic lymphocytic leukemia (CLL). Obinutuzumab (GA101) is an optimized (i.e. glycoengineered